Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer.
Cancer, 1979/7;44(1):32-4.
Yap HY, Blumenschein GR, Tashima CK, Hortobagyi GN, Buzdar AU, Wiseman CL
PMID: 222433
Impact factor: 6.921
Abstract
Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5-FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristing 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.
MeSH terms
Adult; Aged; Breast Neoplasms; Drug Resistance; Drug Therapy, Combination; Female; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Remission, Spontaneous; Time Factors; Vincristine
More resources
EndNote: Download